Some pharmacodynamic aspects on long-acting β-adrenoceptor agonists
- 1 June 1996
- journal article
- review article
- Published by Elsevier in General Pharmacology: The Vascular System
- Vol. 27 (4) , 575-580
- https://doi.org/10.1016/0306-3623(95)02052-7
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Partial Agonism and Functional Selectivity: A Study on β-Adrenoceptor Mediated Effects in Tracheal, Cardiac and Skeletal MuscleActa Pharmacologica et Toxicologica, 2009
- Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilatorLife Sciences, 1993
- The pharmacology of salmeterolLife Sciences, 1993
- Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma.BMJ, 1993
- Atypical molecular pharmacology of a new long-acting β2-adrenoceptor agonist, TA 2005European Journal of Pharmacology: Molecular Pharmacology, 1992
- Studies on the Interaction between Formoterol and Salmeterol in Guinea‐Pig Tracheain VitroBasic & Clinical Pharmacology & Toxicology, 1992
- Tracheal Relaxing Effects and β2-Selectivity of TA-2005, a Newly Developed Bronchodilating Agent, in Isolated Guinea Pig TissuesThe Japanese Journal of Pharmacology, 1991
- Formoterol fumarate, a new β2‐adrenoceptor agonistAllergy, 1989
- Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.Thorax, 1988
- Conjugates of catecholamines. 1. N-Alkyl-functionalized carboxylic acid congeners and amides related to isoproterenolJournal of Medicinal Chemistry, 1983